Horizon Space Acquisition II (HSPT) agreed to merge with SL Bio, which is developing cellular and gene therapies for cancer treatment.
The combined entity will be listed on the Nasdaq, and shareholders of Horizon Space Acquisition and SL Bio will get shares in the newly formed company.
The transaction was approved by both boards and is expected to close late this year, the companies said Monday in a statement.
The new company will be led by SL Bio Chief Executive Officer William Wang.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。